Auris Medical Announces Launch of New Corporate Website
16 Julio 2021 - 8:00AM
Hamilton, Bermuda, July 15, 2021 – Auris Medical
Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing
unmet medical needs through RNA therapeutics, allergy and viral
infection protection, and inner ear therapeutics, today announced
the launch of its newly-designed corporate website
www.aurismedical.com. The new website features a streamlined and
modern design and also reflects the Company’s recently announced
strategic repositioning.
“We are proud to present our projects and
products as well as the science behind them through a completely
redesigned website“, commented Thomas Meyer, Auris Medical’s
founder, Chairman and CEO. “Importantly, the new website reflects
the Company’s recent strategic move into RNA therapeutics, while
highlighting the exciting prospects for its traditional
businesses.” As recently announced, Auris Medical is planning to
change its name to Altamira Therapeutics, subject to approval by a
special general meeting of shareholders on July 21, 2021, and to
divest or spin off its traditional businesses in respiratory and
inner ear therapeutics with the aim of unlocking shareholder
value.
About Auris Medical
Auris Medical is dedicated to developing
therapeutics that address important unmet medical needs. The
Company is currently active in three areas: the development of RNA
therapeutics for extrahepatic therapeutic targets (OligoPhore™ /
SemaPhore™ platforms; preclinical), nasal sprays for protection
against airborne viruses and allergens (Bentrio™; commercial) or
the treatment of vertigo (AM-125; Phase 2), and the development of
therapeutics for intratympanic treatment of tinnitus or hearing
loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in
2003 and is headquartered in Hamilton, Bermuda with its main
operations in Basel, Switzerland. The shares of Auris Medical
Holding Ltd. trade on the NASDAQ Capital Market under the symbol
“EARS.” The Company will change its name to “Altamira Therapeutics
Ltd.” and its ticker symbol to “CYTO”, subject to approval by a
Special General Meeting of shareholders to be held on July 21,
2021.
Forward-looking Statements
This press release may contain statements that
constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical facts and may include statements
that address future operating, financial or business performance or
Auris Medical’s strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as “may”,
“might”, “will”, “should”, “expects”, “plans”, “anticipates”,
“believes”, “estimates”, “predicts”, “projects”, “potential”,
“outlook” or “continue”, or the negative of these terms or other
comparable terminology. Forward-looking statements are based on
management’s current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, the approval and
timing of commercialization of AM-301, Auris Medical’s need for and
ability to raise substantial additional funding to continue the
development of its product candidates, the timing and conduct of
clinical trials of Auris Medical’s product candidates, the clinical
utility of Auris Medical’s product candidates, the timing or
likelihood of regulatory filings and approvals, Auris Medical’s
intellectual property position and Auris Medical’s financial
position, including the impact of any future acquisitions,
dispositions, partnerships, license transactions or changes to
Auris Medical’s capital structure, including future securities
offerings. These risks and uncertainties also include, but are not
limited to, those described under the caption “Risk Factors” in
Auris Medical’s Annual Report on Form 20-F for the year ended
December 31, 2020, and in Auris Medical's other filings with the
SEC, which are available free of charge on the Securities Exchange
Commission's website at: www.sec.gov. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those indicated. All forward-looking statements and all
subsequent written and oral forward-looking statements attributable
to Auris Medical or to persons acting on behalf of Auris Medical
are expressly qualified in their entirety by reference to these
risks and uncertainties. You should not place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date they are made, and Auris Medical does not undertake
any obligation to update them in light of new information, future
developments or otherwise, except as may be required under
applicable law.
Investor contact:
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Auris Medical (NASDAQ:EARS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024